

# A GRIPing Story? Use of the GRIPP2 Checklist for Reporting Patient and Public Involvement in Research

POSTER #63

Karen Woolley<sup>a,b,c</sup> (ORCID: 0000-0003-4626-7723), Amanda Boughey<sup>d</sup>, Sarah McSorley<sup>d</sup>, Simon R. Stones<sup>c,d,e</sup> (ORCID: 0000-0002-5943-1310), Jacqui Oliver<sup>d</sup>

<sup>a</sup>Adjunct Professor, University of Queensland, Brisbane, Australia; <sup>b</sup>Adjunct Professor, University of the Sunshine Coast, Sippy Downs, Australia; <sup>c</sup>Caregiver author; <sup>d</sup>Envision Pharma Group, Wilmslow, Cheshire, UK; <sup>e</sup>Patient author



Key Takeaway

The GRIPP2 guidelines are rarely mentioned (2%) in PPI\* publications, limiting evidence-based best practice for PPI

Aims

GRIPP2

Use

Strong

Weak

PPI evidence base

## Background

- The original Guidance for Reporting Involvement of Patients and the Public (GRIPP)<sup>1</sup> and the updated GRIPP2 checklists<sup>2,3</sup> were developed to enhance the reporting of patient and public involvement (PPI) in research. There are 2 GRIPP2 checklists:
  - Long form: 34 items; for when PPI is the primary focus of the research
  - Short form: 5 items; for when PPI is not the primary focus of the research

GRIPP2 aims “...to improve the quality, transparency, and consistency of the international patient and public involvement (PPI) evidence base...”  
Staniszewska S, et al. 2017<sup>2,3</sup>

- Stakeholders involved in publishing PPI research (eg, authors, publication professionals, journal editors, and publishers) could support the use and aims of GRIPP2
- However, real-world evidence on how GRIPP2 is being used is limited<sup>4</sup>

\*PPI refers to research being carried out “with” or “by” members of the public rather than “to”, “about”, or “for” them<sup>5</sup>

## Objectives

We investigated:

- How have PPI publications changed over time?
- How many PPI publications mention GRIPP2?
- What were the characteristics of PPI publications mentioning GRIPP2?
- How do GRIPP2 items compare with certain journal requirements for reporting PPI?

## Methods

- We searched PubMed from inception to identify PPI publications and then generated a dataset of PPI articles following publication of GRIPP2

PPI publications

PubMed 8/2/2017 to 12/31/2023  
[Title/Abstract] = “Patient and public involvement”

→

Mention GRIPP2

[All fields] = “GRIPP2”

→

Free full text

Online journal and repository searches

## Results

### 1. How have PPI publications changed over time?

- The number of PPI publications has increased rapidly

| Year of publication | Number of PPI publications |
|---------------------|----------------------------|
| 2001                | 0                          |
| 2002                | 0                          |
| 2003                | 0                          |
| 2004                | 0                          |
| 2005                | 0                          |
| 2006                | 0                          |
| 2007                | 0                          |
| 2008                | 0                          |
| 2009                | 0                          |
| 2010                | 0                          |
| 2011                | 10                         |
| 2012                | 10                         |
| 2013                | 10                         |
| 2014                | 10                         |
| 2015                | 10                         |
| 2016                | 10                         |
| 2017                | 10                         |
| 2018                | 10                         |
| 2019                | 10                         |
| 2020                | 10                         |
| 2021                | 10                         |
| 2022                | 10                         |
| 2023                | 10                         |

### 2. How many PPI publications mention GRIPP2?

- Almost all PPI publications, published since GRIPP2, did **not** mention GRIPP2

98%

Only 2% (n = 28) of 1312 PPI publications mentioned GRIPP2

### 3. What were the characteristics of PPI publications mentioning GRIPP2?

- Of the 28 PPI publications mentioning GRIPP2, 5 did not report research results (article types: methods; protocol; letter) and 3 were not available with free full text

Characteristics of free full-text research PPI publications with real-world use of GRIPP2 (n = 20)

|                            |                                                                 |
|----------------------------|-----------------------------------------------------------------|
| Article type               | Most frequent: Research article (11; 55%)                       |
| Country of first author    | Most frequent: UK (12; 60%)                                     |
| Country of funder          | Most frequent: UK (9; 45%)                                      |
| Therapeutic area           | Most frequent: General (not therapeutic area specific) (9; 45%) |
| Language                   | Most frequent: English (20; 100%)                               |
| Patient authorship*        | 8; 40%                                                          |
| Medical writer use         | 0; 0%                                                           |
| Industry sponsor           | 0; 0%                                                           |
| Use of GRIPP2 as a keyword | 1; 5%                                                           |

\* Patient authors may encourage the use of GRIPP2 or work with those who do.<sup>6</sup> Patient authorship (40%) in these PPI publications is relatively high in contrast to patient authorship in patient experience publications (0.2%).<sup>7</sup>

- Of these 20 publications:
  - 14 (70%) used GRIPP2 for purposes other than PPI reporting (eg, guide data collection; assess data quality); 6 (30%) used GRIPP2 to report on PPI (eg, how PPI influenced the study)
  - 8 (40%) included a GRIPP2 form with the publication
    - 6 (75%) as a supplement; 2 (25%) within the publication
  - 5 (63%) completed the form by referring only to page numbers, 2 (25%) included full-text responses, and 1 (12%) had both full-text and page numbers
  - 5 (63%) used the short form; 3 (37%) used the long form
    - Form choice may have been inappropriate; of the 5 publications with a short form, 4 (80%) had PPI as a primary focus but did not use the recommended long form

### 4. How do GRIPP2 items compare with certain journal requirements for reporting PPI?

- The specific requirements for PPI reporting differ between the 2 versions of GRIPP2 and between the requirements issued by some journals<sup>8,9</sup>
- If variations continue, inefficiencies and inconsistencies in PPI reporting are likely

## Limitations

- Results are limited by PubMed’s database and searchability functions and by analyzing PPI reporting guidelines from 2 journals<sup>8,9</sup>

## Conclusions

- Real-world evidence indicates that the aims of GRIPP2 are not being met
  - Although PPI publications are increasing rapidly, GRIPP2 is rarely mentioned
  - If used, the GRIPP2 form is being completed in variable, potentially inefficient and inappropriate, ways
  - Publication professionals could help authors use GRIPP2 for PPI publications

| GRIPP2 Report Card |         |              |             |           |
|--------------------|---------|--------------|-------------|-----------|
| PPI evidence base  |         |              |             |           |
| GRIPP2             | Quality | Transparency | Consistency |           |
| Aims               | ✓       | ✓            | ✓           | =  Strong |
| Use                | ✗       | ✗            | ✗           | =  Weak   |

- A multistakeholder-driven update to GRIPP2 and consideration of incentives for standardized, complete, transparent, and efficient reporting may be warranted<sup>4,10-12</sup>

## Has the time come?

“As the field of PPI develops, we expect further development of GRIPP2 to refine and update the guidance”

Brett J, et al. 2017<sup>13</sup>

Please scan this QR code to hear an audio summary of the lead author’s perspectives

Contact: Professor Karen L. Woolley; kwoolley535@gmail.com

## References

- Staniszewska S, et al. *Int J Technol Assess Health Care*. 2011;27(4):391-399.
- Staniszewska S, et al. *BMJ*. 2017;358:j3453.
- Staniszewska S, et al. *Res Involv Engagem*. 2017;3:13.
- Jones J, et al. *Res Involv Engagem*. 2021;7(1):52.
- NIHR. <https://sites.google.com/nihr.ac.uk/pi-standards/standards/definitions>. Accessed March 19, 2024.
- Vanderhout S, et al. *J Clin Epidemiol*. 2023;164:35-44.
- Lobban D, et al. *Curr Med Research Opin*. 2023;39(suppl 1):5-39.
- The BMJ. [https://www.bmj.com/sites/default/files/attachments/resources/2018/03/PPI\\_in\\_Research.pdf](https://www.bmj.com/sites/default/files/attachments/resources/2018/03/PPI_in_Research.pdf). Accessed March 19, 2024.
- Davis S, et al. *Lancet Psychiatry*. 2024;11(1):8-9.
- Woolley KL. [https://www.linkedin.com/posts/prof-karen-woolley\\_reporting-lived-experience-work-activity-7149973934652731393-Zkrd?utm\\_source=share&utm\\_medium=member\\_desktop](https://www.linkedin.com/posts/prof-karen-woolley_reporting-lived-experience-work-activity-7149973934652731393-Zkrd?utm_source=share&utm_medium=member_desktop). Accessed March 19, 2024.
- Woolley KL. <https://twitter.com/KWProScribe/status/1744210454434680878>. Accessed March 19, 2024.
- Woolley KL, et al. Patient authorship of medical research publications – an evolution, revolution, and solution? (In press). *J Learned Publishing*. 13.
- Brett J, et al. *BMJ Open*. 2017;22;7(10):e016948.

## Disclosures and Acknowledgments

All authors participated in the research, were actively involved in preparing the abstract, and have approved the final poster. KW is a consultant to, and shareholder in, Envision Pharma Group. AB, SM, SRS, and JO are employees of, and own share options in, Envision Pharma Group, a healthcare communications company that is funded by pharmaceutical companies. SRS has received honoraria from Future Science Group (now part of Taylor & Francis), is a trustee of RAISE (a charitable incorporated organization registered in England and Wales, Number 1180704), is a member of the ISMP Patient Engagement Task Force, and is a member of the EULAR PARE Committee. Editorial and graphical support were provided by Miranda Dixon and Sally Logan of Envision Pharma Group.

Presented at the 20th Annual Meeting of the International Society for Medical Publication Professionals (April 29 to May 1, 2024; Washington DC, USA)